Intersect ENT, Inc
XENT
XENT was delisted on the 12th of May, 2022.
112 hedge funds and large institutions have $521M invested in Intersect ENT, Inc in 2019 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 44 increasing their positions, 33 reducing their positions, and 20 closing their positions.
430% more call options, than puts
Call options by funds: $16.1M | Put options by funds: $3.05M
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
33% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 33
0% more funds holding
Funds holding: 112 → 112 (0)
0% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 20
25% less capital invested
Capital invested by funds: $690M → $521M (-$169M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$25.3M |
| 2 |
BC
Broadfin Capital
New York
|
+$14.2M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$9.96M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.28M |
| 5 |
PVI
Pura Vida Investments
New York
|
+$6.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$31.5M |
| 2 |
Millennium Management
New York
|
-$16.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.98M |
| 5 |
HM
HealthCor Management
New York
|
-$4.26M |
XENT Hedge Fund Activity: Q3 2019 in Review
112 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Intersect ENT, Inc (XENT) for Q3 2019, worth a combined $521M — down 25% from $690M a quarter earlier.
Fund positioning in XENT was balanced in Q3 2019: 20 funds opened new positions, 20 closed out, 44 added to existing stakes and 33 trimmed.
The largest buyer was UBS Group, adding an estimated $25.3M. The largest seller was Invesco, cutting an estimated $31.5M.
- 112 institutional investors held Intersect ENT, Inc (XENT) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $521M of Intersect ENT, Inc stock for Q3 2019, down 25% quarter-over-quarter.
- 20 funds opened new Intersect ENT, Inc positions in Q3 2019 and 20 closed out, a net change of 0 holders.
- The largest Intersect ENT, Inc buyer in Q3 2019 was UBS Group, an estimated $25.3M added.
- The largest Intersect ENT, Inc seller in Q3 2019 was Invesco, an estimated $31.5M sold.
Based on aggregated 13F filings for Q3 2019.